BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study

• Published in: Annals of internal medicine Vol. 101; no. 4; p. 447
• Main Authors: Bakemeier, R F, Anderson, J R, Costello, W, Rosner, G, Horton, J, Glick, J H, Hines, J D, Berard, C W, DeVita, Jr, V T
• Format: Journal Article
• Language: English
• Published: United States 01.10.1984
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Blood Cell Count; Carmustine - administration & dosage; Carmustine - adverse effects; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide - administration & dosage; Cyclophosphamide - adverse effects; Female; Gastrointestinal Diseases - chemically induced; Hematologic Diseases - chemically induced; Hodgkin Disease - drug therapy; Hodgkin Disease - pathology; Humans; Male; Mechlorethamine - administration & dosage; Mechlorethamine - adverse effects; Neoplasm Staging; Peripheral Nervous System Diseases - chemically induced; Prednisone - administration & dosage; Prednisone - adverse effects; Procarbazine - administration & dosage; Procarbazine - adverse effects; Random Allocation; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vincristine - administration & dosage; Vincristine - adverse effects

Two chemotherapy regimens for treatment of patients with advanced Hodgkin's disease, BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone) and MOPP (mechlorethamine hydrochloride, vincristine, procarbazine, and prednisone), were compared in a randomized prospective stu...